{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Orilissa", "query": { "intervention": "Orilissa" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Orilissa&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T18:05:56.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03213457", "title": "A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Estradiol/Norethindrone Acetate", "type": "DRUG" }, { "name": "Placebo for Elagolix", "type": "DRUG" }, { "name": "Elagolix", "type": "DRUG" }, { "name": "Placebo for E2/NETA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 681, "start_date": "2017-07-07", "completion_date": "2023-12-06", "has_results": true, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 188, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03213457" }, { "nct_id": "NCT04333576", "title": "Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "Elagolix", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Combined Oral Contraceptive", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 800, "start_date": "2020-08-10", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 176, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 134 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04333576" }, { "nct_id": "NCT01403038", "title": "An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Folliculogenesis" ], "interventions": [ { "name": "elagolix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 216, "start_date": "2011-06", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2013-01-08", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 20, "location_summary": "Colorado Springs, Colorado • Denver, Colorado • Lonetree, Colorado + 14 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lonetree", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01403038" }, { "nct_id": "NCT03271489", "title": "Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroids" ], "interventions": [ { "name": "Elagolix", "type": "DRUG" }, { "name": "Estradiol /norethindrone acetate (E2/NETA)", "type": "DRUG" }, { "name": "E2/NETA Placebo", "type": "OTHER" }, { "name": "Elagolix Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 478, "start_date": "2017-09-13", "completion_date": "2024-06-28", "has_results": true, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 155, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271489" }, { "nct_id": "NCT04039204", "title": "Elagolix for Fertility Enhancement Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometriosis", "Unexplained Infertility" ], "interventions": [ { "name": "Elagolix", "type": "DRUG" }, { "name": "Ortho Cyclen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "42 Years", "sex": "FEMALE", "summary": "18 Years to 42 Years · Female only" }, "enrollment_count": 10, "start_date": "2022-01-15", "completion_date": "2023-08-09", "has_results": true, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04039204" }, { "nct_id": "NCT06798571", "title": "Role of Menopause in Thermoregulation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Menopause", "Aging" ], "interventions": [ { "name": "Elagolix Oral Tablet", "type": "DRUG" }, { "name": "Estradiol patch", "type": "DRUG" }, { "name": "cellulose placebo", "type": "OTHER" }, { "name": "placebo patch", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Penn State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Years", "maximum_age": "64 Years", "sex": "FEMALE", "summary": "42 Years to 64 Years · Female only" }, "enrollment_count": 24, "start_date": "2025-03-01", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 1, "location_summary": "University Park, Pennsylvania", "locations": [ { "city": "University Park", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06798571" }, { "nct_id": "NCT02654054", "title": "Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Uterine Fibroids", "Heavy Menstrual Bleeding" ], "interventions": [ { "name": "Elagolix", "type": "DRUG" }, { "name": "Placebo for Estradiol/Norethindrone Acetate", "type": "DRUG" }, { "name": "Estradiol/Norethindrone Acetate", "type": "DRUG" }, { "name": "Placebo for Elagolix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "FEMALE", "summary": "18 Years to 51 Years · Female only" }, "enrollment_count": 413, "start_date": "2015-12-22", "completion_date": "2018-12-12", "has_results": true, "last_update_posted_date": "2020-06-29", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 92, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Hawaiian Gardens", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02654054" }, { "nct_id": "NCT06253702", "title": "Brain Blood Flow Responses to Stress: Sex Differences", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cerebrovascular Disorders" ], "interventions": [ { "name": "Indomethacin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Orilissa", "type": "DRUG" }, { "name": "Testosterone gel", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 22, "start_date": "2024-07-24", "completion_date": "2025-05-31", "has_results": false, "last_update_posted_date": "2025-07-18", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06253702" }, { "nct_id": "NCT03951077", "title": "Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycystic Ovary Syndrome" ], "interventions": [ { "name": "Elagolix", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "18 Years to 35 Years · Female only" }, "enrollment_count": 118, "start_date": "2019-08-12", "completion_date": "2021-02-10", "has_results": true, "last_update_posted_date": "2022-06-08", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Mobile, Alabama • San Diego, California + 43 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03951077" }, { "nct_id": "NCT03886220", "title": "A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Uterine Fibroids" ], "interventions": [ { "name": "Elagolix", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "51 Years", "sex": "FEMALE", "summary": "18 Years to 51 Years · Female only" }, "enrollment_count": 82, "start_date": "2019-04-12", "completion_date": "2021-04-28", "has_results": true, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-09-06T18:05:56.521Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03886220" } ] }